The FDA has approved a new drug called Vabrinty (leuprolide acetate) for the treatment of advanced prostate cancer. Vabrinty is a type of hormone therapy known as a GnRH agonist. It works by lowering the amount of testosterone in the body, which can slow the growth of prostate cancer cells. The drug is given as an injection under the skin by a healthcare provider. It comes in different versions that last for one, three, four, or six months. This allows doctors to choose a dosing schedule that fits each patient's needs.
This approval is for people with advanced prostate cancer, meaning the cancer has spread or is at a high risk of spreading. Vabrinty is not a cure, but it can help control the disease. The FDA based its approval on the known effects of similar drugs in this class, not on new clinical trials. That means its safety and effectiveness are expected to be similar to other GnRH agonists already on the market.
If you or a loved one has advanced prostate cancer, this new option may offer more convenience. However, it is important to talk with your doctor about whether Vabrinty is right for you. Your doctor can explain the benefits and risks, and help you decide on the best treatment plan.
